Biomarkers predicting good prognosis among patients receiving immunosuppressive treatment in IgA nephropathy: the promising role of serum TGF-β1 and MCP-1

Citations

WEB OF SCIENCE

0
Citations

SCOPUS

0

초록

Background IgA nephropathy (IgAN) exhibits a highly variable clinical course. As responses to immunosuppressive therapy remain inconsistent, reliable prognostic markers are critically required to identify patients who can show a good response to immunosuppressive treatments. Methods This prospective cohort study enrolled adults with biopsy-proven IgAN from 2010-2020. Good prognosis was defined as a >= 50% reduction in the urine protein-to-creatinine ratio (uPCR) or <0.5 g/g with preserved estimated glomerular filtration rate 1 year after biopsy. Serum and urine cytokines/chemokines (TGF-beta 1, MCP-1, RANTES, and VEGF) and intrarenal CD45+, CD3+, CD20+, and Ki-67+ cells were analyzed. Results Among the 202 patients, 120 (59.4%) had a good prognosis and showed a significantly lower risk of end-stage kidney disease over a 10-year follow-up. Multivariable analyses identified immunosuppressive therapy, low histologic grade, lower uPCR, absence of hypertension, higher serum TGF-beta 1 levels, and reduced intrarenal CD45+ and CD3+ cell infiltration as independent predictors of good prognosis. Among patients receiving immunosuppressive therapy, higher serum TGF-beta 1 (adjusted odds ratio [aOR], 1.16; 95% confidence interval [CI], 1.04-1.31) and lower serum MCP-1 (aOR, 0.99; 95% CI, 0.97-1.00) independently predicted good prognosis, whereas less intrarenal CD20+ cell infiltration (aOR, 0.22; 95% CI, 0.07-0.73) independently predicted good prognosis in patients receiving supportive care only. Conclusions Serum TGF-beta 1 and MCP-1 levels may serve as biomarkers of favorable prognosis among patients with IgAN receiving immunosuppressive therapy, whereas intrarenal CD20+ cell infiltration may reflect poor prognosis under supportive care. Integrating serum cytokine profiles and tissue immune signatures may help inform individualized treatment decisions for IgAN.

키워드

IgA nephropathy; immunosuppressive therapy; MCP-1; prognosis; TGF-beta 1; LONG-TERM OUTCOMES; LATENT TGF-BETA-1; GROWTH-FACTOR; DOUBLE-BLIND; TGF-BETA; PROTEIN-1; FIBROSIS; PLACEBO; MICE
제목
Biomarkers predicting good prognosis among patients receiving immunosuppressive treatment in IgA nephropathy: the promising role of serum TGF-β1 and MCP-1
저자
Jeon, Junseok; Yoon, Youngmin; Lee, Kyungho; Moon, Heasil; Lee, Jung Eun; Kwon, Ghee Young; Huh, Wooseong; Jang, Hye Ryoun
DOI
10.3389/fimmu.2026.1852831
발행일
2026-06-24
유형
Article
저널명
Frontiers in Immunology
권
17